Xencor Reports Q3 Earnings Beat with Significant Revenue Growth and Positive Clinical Data
Xencor (XNCR) reported third-quarter financial results that significantly exceeded analyst expectations. The company posted a GAAP EPS of $0.50, beating estimates by $0.83, while revenue reached $116.52 million—a 454.9% increase year-over-year and a beat of $53.53 million. Beyond the financial results, Xencor highlighted positive Phase 1 clinical data for its XmAb819 candidate in advanced clear cell renal cell carcinoma (ccRCC). This development has bolstered investor confidence, with market analysts noting the potential for an FDA accelerated approval pathway.
Tickers: $XNCR
Topics: biotechnology clinical trial results earnings beat revenue growth